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Abstract. Background/Aim: In 2016 in the United States, 7 of
10 patients were estimated to die following lung cancer
diagnosis. This is due to a lack of a reliable screening method
that detects early-stage lung cancer. Our aim is to accurately
detect early stage lung cancer using algorithms and protein
biomarkers. Patients and Methods: A total of 1,479 human
plasma samples were processed using a multiplex immunoassay
platform. 82 biomarkers and 6 algorithms were explored. There
were 351 NSCLC samples (90.3% Stage I, 2.3% Stage II, and
7.4% Stage III/IV). Results: We identified 33 protein biomarkers
and developed a classifier using Random Forest. Our test
detected early-stage Non-Small Cell Lung Cancer (NSCLC) with
a 90% accuracy, 80% sensitivity, and 95% specificity in the
validation set using the 33 markers. Conclusion: A specific, non-
invasive, early-detection test, in combination with low-dose
computed tomography, could increase survival rates and reduce
false positives from screenings.
According to the American Cancer Society, on a global scale,
lung cancer is the leading cause of cancer-related incidence
and death at 2.09 million cases and 1.76 million deaths in
2018 (1). By 2016, in the US, an estimated 538,243 living
individuals were diagnosed with lung and bronchus cancer
(2). An additional 228,150 new cases with an estimated
142,670 deaths are expected in 2019 (3). 
Lung cancer originates in the lungs, but can metastasize to
other organs in the body. It is classified based on the
histological profile of the tumor cell and predominantly falls
into two major categories: i) small cell lung cancer (SCLC,
13%) and ii) non-small cell lung cancer (NSCLC, 84%) (3).
Detection at Stage I or II for NSCLC can offer good prognosis.
Symptoms and detection. Current methods of detecting lung
cancer include a chest x-ray (CXR), computed tomography
(CT) scan, magnetic resonance imaging (MRI), positron
emission tomography (PET) scan, sputum analysis, and lung
biopsy. Despite the advancement in technology and the
extensive cancer research, 57% of lung cancer patients are
diagnosed only after a tumor has metastasized to a different
location. Under these circumstances, there is little chance of
a cure, and the 5-year survival rate is less than 6% (2). Late
diagnosis of lung cancer can be attributed to: i) primarily the
lack of symptoms at early-stage lung cancer (4) ii)
misdiagnosis of the disease since early symptoms (persistent
cough, shortness of breath, chest pain, wheezing, and
hemoptysis) are often misinterpreted (5) iii) the lack of
proven benefit for lung cancer screening until recently (6),
and iv) cost effect and limited access to state-of-the-art
detection methods in indigent populations (7). 
It is evident that the sooner lung cancer is diagnosed, the
better the prognosis for the patient. However, only 16% of
patients were diagnosed when the disease was still restricted
to the lungs and even for these, only 57.4% survived 5 years
(8). Based on the 2016 Cancer Statistics Review by SEER
(8), the 5-year survival rate decreased to 30.8% and 5.2% for
patients with regional and distant stage lung cancer,
respectively. Only 19.4% of all diagnosed lung cancer
patients from 2009-2015 survived 5 years.
NLST clinical trial. In 2010, a US clinical trial, sponsored by
the National Lung Screening Trial (NLST), showed a 20%
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decrease in lung cancer deaths for high-risk patients who
were screened with low-dose spiral computed tomography
(LDCT scans) compared to standard chest x-ray (CXR). The
NLST patient population consisted of 53,454 current or
former smokers with a ≥30 pack-year smoking history
between 55-74 years of age and no history or symptoms of
lung cancer. The results of the NLST study (9, 10) were: 
i) patient adherence rate to screening was greater than 90%,
ii) the rate of positive screen tests was 24.2% with LDCT
and 6.9% with radiography, 
iii) false positive rates (lung mass) were 96.4% for the
LDCT and 94.5% for the CXR screened group,
iv) the mortality rate from lung cancer was 20% lower with
LDCT compared to the CXR screened group
v) the rate of death from any cause was 6.7% lower with
LDCT compared to the CXR screened group.
We had a few caveats concerning the NLST study. First,
due to the substantial pack history of the NLST participants,
it was not known whether these findings were relevant to
individuals who were non-smokers or those who smoked
less. Second, screening using LDCT and radiography showed
a high rate of false positives which can lead to unnecessary
lung biopsy, surgery, other follow-up diagnostic tests, and
stress. Additional factors associated with LDCT and
radiography screening that warrants further exploration
include: i) the economic implications of over diagnosis, ii)
the radiation exposure from multiple scans may lead to
development of other cancers, and iii) the access to high-
quality screening in certain settings.
Based on the NLST study, there is clearly a need for an
accurate, early-stage, non-invasive test to further stratify risk
patients with small, indeterminate nodules primarily
identified using CT scanning. Our study aimed to identify
potential biomarkers and an algorithm to predict early stage
NSCLC with high accuracy using human plasma samples for
use as an adjunctive test for lung cancer screening.
Patients and Methods 
The patients from our selected population for the Lung Cancer
Detector Test-1 (LCDT1) were 40+ years old, long-term smokers,
and had been diagnosed with indeterminate nodules in the lungs.  
Study population. This study consisted of 1,479 subjects (2,958
samples) distributed in the following cohorts: i) asthma sufferers,
ii) non-smokers, iii) smokers, iv) NSCLC, and v) other cancers.
Asthma (also includes other respiratory diseases, e.g. chronic
obstructive pulmonary disease (COPD)) was included in the study
population as symptoms share similarities with early signs of lung
cancer. Other cancers (e.g. breast, prostate, ovarian, pancreatic, and
colorectal cancer) were included to evaluate specificity to lung
cancer. Table I summarizes the main criteria used to select samples
for each cohort. Samples originated from Bulgaria, Romania,
Russia, Ukraine and the United States and consisted of a mixture of
Caucasian, African-American, and Hispanic populations.
Training set. The training set consisted of 554 Subjects (1,108 samples)
ran in duplicates to evaluate 82 biomarkers and 6 multivariate analysis
methods and to train the selected algorithm. There were: i) 160 NSCLC
which served as a positive control, ii) 140 healthy non-smokers which
served as our negative control, iii) 33 asthma sufferers, iv) 131 high-
risk smokers, and v) 90 other cancers. Protein biomarker
concentrations, gender, and race were included in the analysis. Subjects
ranged from 25-94 years old and were distributed between female and
male cohorts as shown in Table II. Patient samples consisted
predominantly of Caucasians and some African-Americans and
Hispanics. Most NSCLC samples were Stage I (Table III). All samples
were randomized and cohorts were distributed evenly across the total
plates of the study using R and Python. 
Validation set. To verify the performance of the selected biomarkers
and the final algorithm, a blind and independent sample set of 925
subjects (1,850 samples) was processed.
Sample collection and handling. Human plasma samples were
obtained from five blood banks: Asterand, BioReclamation,
BioSource, Geneticist, and Proteogenex. Clinical information, such
as age, gender, pathology and stage, race, origin, smoking status,
and sample collection dates, was obtained. Sample were collected
and processed according the respective blood bank’s protocols.
Plasma samples were transported on dry ice overnight to our storage
site in Michigan City, Indiana, USA. Vials were inspected visually
for damage upon receipt and were stored at –80˚C until analysis. 
Selection of biomarkers. Eighty-two commercially available protein
analytes were used for the initial screening. The list was narrowed
down to 33 biomarkers with a diagnostic potential for early stage
lung cancer: The 33 biomarkers were CA-125, CEA, CYFRA21-1,
EGFR/HER1/ErBB1, Gro-Pan, HGF, IL-10, IL-12p70, IL-16, IL-2,
IL-4, IL-5, IL-7, IL-8, IL-9, Leptin, LIF, MCP-1, MIF, MIG, MMP-
7, MMP9, MPO, NSE, PDGF-BB, Rantes, Resistin, sFasL, SAA,
sCD40-ligand, sICAM-1, TNFRI, and sTNFRII.
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Table I. Baseline criteria for selecting NSCLC and other samples.
Samples           Gender      Age       Cancer stage         Smoking status
NSCLC               M/F         NA        IA/B, IIA/B     Non-smoker, smoker
Non-smoker       M/F      ≥25 y/o            NA                   Non-smoker
Smoker                M/F      ≥40 y/o            NA                       Smoker
Asthma                M/F         NA               NA            Non-smoker, smoker
Other cancers      M/F         NA          All stages       Non-smoker, smoker
All sample groups consisted of a mixture of Caucasian, African-
American and Hispanic. The NSCLC group mainly consisted of patients
diagnosed with Stage I and II NSCLC regardless of age and smoking
status. 13 out of 160 NSCLC samples were stage III and IV. The Non-
Smoker group consisted of healthy individuals that were 25 y/o or older,
non-smokers with no diagnosis of any cancer. The Smoker group
included individuals 40 y/o, smoked 1 pack per day for 10 years, and
no diagnosis of any cancer. The Asthma group included individuals
diagnosed with asthma (and with other respiratory diseases, e.g. COPD)
but no lung cancer, regardless of age and smoking status. Other cancers
included patients diagnosed with breast, ovarian, prostate, pancreatic,
or colon-rectal cancer.
Our process in selecting these biomarkers included: i) a statistical
importance as measured by the decrease in Gini impurity, ii)
analysis of ratio of biomarker distribution between healthy and
diseased states, iii) the biomarker’s overall patterns observed for
specific cohorts, iv) a known biological relevance of these markers
for NSCLC via a physio-pathological pathway and/or through
literature, and v) the biomarkers’ performance in multiplexed system
using the selected developed algorithm model. 
Multiplexed immunoassay procedure. This study used a custom-
made multiplexed immunoassay developed by Millipore (Billerica,
MA, USA) to measure the concentration of selected biomarkers in
human plasma samples. The reagent kits were designed on magnetic
beads using a capture sandwich immunoassay format. The assay
was performed according to the manufacturer’s protocol. Briefly,
samples were thawed on ice or at 4˚C and were visually inspected
for turbidity, hemolysis, lipaemia, and other signs of degradation.
The plates were read using the FlexMap 3D (Luminex
Technologies, Austin, TX, CA), which measures the fluorescence of
the beads and of the bound SA-PE. The Bio-Plex Manager 6.1 (Bio-
Rad Laboratories, Hercules, CA, USA) was used for data
acquisition using a 5PL logistic curve to obtain analyte
concentrations. Sample processing was performed by Eve
Technologies Corporation (Calgary, Alberta, Canada).
Multivariate classification and analysis. The multivariate
classification methods that were evaluated independently included
the Support Vector Machine (SVM), Random Forest (RF), Penalized
Regression (LASSO and Ridge Regression), Adaptive Boosting
(AdaBoost), and decision rules found by Genetic Algorithms. These
algorithms considered two independent measurements of 33
biomarkers from a single subject, their gender and smoking status,
and classified each measurement as positive or negative for NSCLC.
If any of the measurement for a plasma sample was classified as a
subject with NSCLC by the algorithm, then the subject was
considered positive for NSCLC. The algorithm that was selected
had the best performance, as measured by its sensitivity and
specificity, as well as the highest level of stability, as measured by
bootstrap estimates of the algorithm’s performance. 
The penalized logistic regression model. When developing
predictive models based on many variables, such as the
concentration of numerous biomarkers for NSCLC, logistic
regression may fail due to non-convergence, (11) or it may be that
regression coefficients for the parameter estimates have a large
variance. By reducing the number of parameters, such as the
number of biomarkers in the model, one can reduce the variance of
the regression coefficients. 
One way to effectively reduce the number of parameters in the
model is to constrain the Lp-norm or L∞-norm of the parameter vector,
β, of the model by some positive values, usually denoted as t. A form
of penalized regression that allows such constraints is the least
absolute shrinkage and selection operator (LASSO) model. The
LASSO model adds the constraint that the L1-norm of the parameter
vector, β, is no greater than some given value, t (i.e., p=1). Ridge
regression is another form of penalized regression that adds the
constraint that the L2-norm of the parameter vector, β, is no greater
than some given value, t (e.g. t=2).
The naïve Bayes classifier. The set of Bayes classifiers are a set of
classifiers based on Bayes’ theorem:
                    P(B/A)P(A)
P(A/B)=
                         P(B)
All classifiers of this type seek to find the probability (P) that an
observation belongs to a class (A or B) given the data for that
observation. The class with the highest probability is the one to
which each new observation is assigned. Theoretically, Bayes
classifiers have the lowest error rates amongst the set of classifiers.
In practice, however, this does not always occur due to violations
of the assumptions made about the data when applying a Bayes
classifier.
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Table II. Age range and number of samples per cohort.
                                                                        Training set                                                                           Validation set
                                                                       (554 subjects)                                                                         (925 subjects)
                                Age range       Median age      No. of female     No. of male      Age range      Median age     No. of female     No. of male     Total
Asthma                       29-83                  59                        25                       8                  19-83                 63                      54                     20              107
Non-smoker                25-77                  55                        70                     70                  45-80                 55                      90                     88              318
NSCLC                       42-94                  66                        78                     82                  42-94                 66                      84                   107              351
Smoker                       44-79                  53                        66                     65                  25-77                 53                      82                     86              299
Other Cancers            29-83                  60                        56                     34                  26-89                 63                    198                   116              404
Total                            25-94                  59                     295                   259                  19-94                 63                    508                   417            1479
Table III. Breakdown of NSCLC stages.
NSCLC stage          Training          Validation         Total         Percentage
                              (78F/82M)       (84F/107M)
IA/B                           147                    170               317             90.3%
IIA/B                              0                        8                   8                2.3%
IIIA/B                             6                        6                 12                3.4%
IVA                                 7                        7                 14                4.0%
Total                           160                    191               351           100.0%
F: Female; M: male.
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Table IV. Median concentrations and p-Values between NSCLC and healthy controls.
                                                                                           Lung cancer (160)                                               Healthy (140)
Biomarker                                  Units                      Median                        Q1, Q3                        Median                         Q1, Q33                      p-Value
CA125                                       U/ml                          6.9                          4.5, 14.4                            4.3                            3.6, 5.2                       <0.001
CCL20/MIP-3α                        pg/ml                      157.6                      112.8, 240.7                      175.9                        104.2, 236.6                     0.087
CEA                                          ng/ml                          3.1                             2, 6.1                              1.9                            1.5, 2.4                         0.001
CXCL11/I-TAC                        pg/ml                        71.2                        41.9, 154.5                        53.0                          34.2, 87.9                       0.288
CXCL9/MIG                             ng/ml                          2.1                          1.3, 4.2                              1.2                            0.7, 2.2                         0.052
CYFRA 21-1                             ng/ml                          2.8                          1.8, 4.9                              3.5                            1.2, 4.7                       <0.001
GM-CSF                                   pg/ml                        42.7                        27.7, 79.2                          41.1                          29.8, 57                          0.019
Granzyme-β                              pg/ml                        65.5                        40.2, 100.2                        62.3                          39.7, 98.9                       0.188
GRO Pan                                   pg/ml                          0.7                          0.3, 2.3                              0.3                            0.2, 0.8                         0.248
HGF                                          pg/ml                      409.9                     281.9, 566.4                      280.2                           192, 409.7                     0.003
IFN-α2                                      pg/ml                      115.9                       85.6, 188.3                      123.0                          88.7, 187.9                     0.662
IFN-β                                        ng/ml                        28.5                        17.7, 39.9                          27.5                          15.9, 35.7                       0.089
IFN-γ                                         pg/ml                        21.5                        13.1, 31.2                          17.5                          12.7, 31.9                       0.462
IL-10                                         pg/ml                        18.0                        13.1, 29.4                          15.8                          10.4, 22.8                       0.006
IL-12P40                                   pg/ml                        36.3                        22.4, 49.3                          39.5                          27.6, 51.4                       0.048
IL-12p70                                   pg/ml                        14.9                        12.9, 20.2                          12.2                            9.8, 25.8                       0.735
IL-13                                         pg/ml                      106.7                       33.5, 219.8                      104.9                          81.8, 345.1                     0.035
IL-15                                         pg/ml                        15.5                        10.8, 20.1                          40.1                             13, 71.1                       0.072
IL-16                                         ng/ml                          0.8                          0.4, 1.4                              0.9                            0.3, 1.6                         0.298
IL-17A                                      pg/ml                      130.6                       87.5, 207.8                      118.5                          84.5, 185.7                     0.672
IL-17F                                       pg/ml                      249.9                     164.2, 327                         265.8                        163.6, 349.6                     0.981
IL-1α                                         pg/ml                      172.2                           90, 345.7                      160.6                        111.2, 306.4                     0.024
IL-1β                                         pg/ml                        13.6                        11.1, 22.2                          13.8                          10.4, 33.7                       0.013
IL-1Rα                                      pg/ml                        69.4                        33.3, 190.9                        97.5                          36.1, 251.5                     0.270
IL-2                                           pg/ml                        18.3                        16.2, 39.8                          21.5                          15.2, 29.8                       0.095
IL-20                                         pg/ml                      271.3                     199.4, 387.7                      232.8                        165.2, 300.4                     0.410
IL-21                                         pg/ml                      294.2                     199.3, 510.4                      316.8                        175.8, 478.5                     0.900
IL-22                                         ng/ml                          2.0                          1.4, 3.0                              2.2                            1.4, 3.0                         0.789
IL-23                                         ng/ml                        24.5                        14.7, 39.6                          23.3                          16.0, 39.8                       0.990
IL-27                                         ng/ml                          4.6                          3.1, 7.5                              4.5                            2.7, 7.6                         0.372
IL-3                                           pg/ml                        10.0                          9.9, 11.1                          11.3                          10.2, 51.2                       0.454
IL-31                                         ng/ml                          2.3                          1.4, 4.1                              2.4                            1.4, 4.2                         0.470
IL-4                                           pg/ml                        70.6                        30.5, 446.7                      202.1                          35.3, 224.1                     0.562
IL-5                                           pg/ml                        67.1                        34.6, 154.4                      104.5                          63.9, 149.7                     0.183
IL-6                                           pg/ml                        22.1                        14.4, 37.3                          24.2                          21.4, 66.1                     <0.001
IL-7                                           pg/ml                        27.4                        14.8, 42.2                          23.1                          12.9, 121.9                     0.336
IL-8                                           pg/ml                        35.4                        15.7, 178.3                        17.1                          14.3, 40.3                       0.068
IL-9                                           pg/ml                        15.6                        13.1, 24.2                          15.1                             12, 65.2                       0.024
IP-10                                          ng/ml                          0.8                          0.5, 1.1                              0.6                            0.4, 0.9                         0.736
Leptin                                        ng/ml                        21.9                          9.5, 37.0                          19.9                            5.6, 54.0                       0.912
LIF                                             pg/ml                        58.4                           32, 98.7                          32.3                          26.8, 55.6                       0.185
MCP-1                                       pg/ml                      553.4                         405, 723.3                      343.1                        245.4, 476.1                   <0.001
MCP-3                                       pg/ml                      103.9                       64.9, 132.7                      124.7                          57.3, 355.5                     0.276
M-CSF                                      ng/ml                          4.5                          2.3, 14.4                            5.0                            4.7, 11.1                       0.029
MIF                                           pg/ml                      398.1                     217.4, 1152.9                    277.3                        176.5, 473.2                     0.638
MIP-1α                                     pg/ml                        45.5                        29.7, 50.8                          42.2                          33.5, 59.1                       0.129
MIP-1β                                      pg/ml                        70.4                        45.4, 89.2                          67.0                          46.4, 81.3                       0.946
MMP-7                                      ng/ml                          4.0                          2.6, 5.5                              2.2                            1.5, 3.1                       <0.001
MMP-9                                      ng/ml                        51.1                        30.4, 90.8                          37.4                          13.4, 61.5                       0.055
MPO                                         mg/ml                         0.1                        0.07, 0.3                              0.1                          0.07, 0.2                         0.060
NGF                                          pg/ml                        90.1                        43.4, 146.1                        80.8                          43.2, 136.5                     0.858
NSE                                           ng/ml                          6.9                          4.4, 10.9                            6.6                            4.5, 9.3                         0.004
OPG                                          pg/ml                      693.5                     515.6, 883.7                      492.4                        380.8, 598.3                   <0.001
PAI-1-(total)                              ng/ml                        73.2                        56.5, 101.8                        54.9                          40.8, 80.4                       0.733
PDGF-AB/BB                           ng/ml                        45.7                        32.1, 78.5                          38.8                          30.3, 53.1                       0.022
PLGF                                         pg/ml                        76.0                        43.4, 116.9                        73.7                          36.5, 95.8                       0.006
Table IV. Continued
The naïve Bayes classifier is one example of a Bayes classifier.
It simplifies the calculations of the probabilities used in classification
by assuming that each class is independent of the other classes given
the data. Naïve Bayes classifiers are used in many prominent anti-
spam filters due to the ease of implantation and speed of
classification but have the drawback that the assumptions required
are rarely met in practice. Tools for implementing naïve Bayes
classifiers as discussed herein are available for the statistical software
computing language and environment, R. For example, the R
package “e1071,” version 1.5-25, includes tools for creating,
processing and using naïve Bayes classifiers.
Neural nets. One way to think of a neural net is as a weighted
directed graph where the edges and their weights represent the
influence each vertex has on the others to which it is connected.
There are two parts to a neural net, the input layer (formed by the
data) and the output layer (the values, which in this case are the
classes to be predicted). Between the input layer and the output
layer is a network of hidden vertices. There may be, depending on
the way the neural net is designed, several vertices between the
input layer and the output layer.
Neural nets are widely used in artificial intelligence and data
mining, but there is the danger that the models the neural nets
produce will over-fit the data (i.e. the model will fit the current data
very well but will not fit future data well). 
Tools for implementing neural nets as discussed herein are
available for the statistical software computing language and
environment, R. For example, the R package “e1071,” version 1.5-
25, includes tools for creating, processing, and using neural nets.
k-Nearest neighbor classifiers. The nearest neighbor classifiers are
a subset of memory-based classifiers. These are classifiers that must
“remember” what is in the training set in order to classify a new
observation. Nearest neighbor classifiers do not require a model to
be fit. To create a k-nearest neighbor (knn) classifier, the following
steps are taken:
i) Calculate the distance from the observation to be classified to
each observation in the training set. The distance can be calculated
using any valid metric, though Euclidian and Mahalanobis distances
are often used.
ii) Count the number of observations amongst the k nearest
observations that belong to each group. The group that has the
highest count is the group to which the new observation is assigned.
Nearest neighbor algorithms have problems dealing with categorical
data due to the requirement that a distance needs to be calculated
between two points but that can be overcome by defining a distance
arbitrarily between any two groups. This class of algorithm is also
sensitive to changes in scale and metric. With these issues in mind,
nearest neighbor algorithms can be very powerful, especially in
large data sets. 
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Table IV. Continued
                                                                                           Lung cancer (160)                                               Healthy (140)
Biomarker                                  Units                      Median                        Q1, Q3                        Median                         Q1, Q33                      p-Value
RANKL                                     ng/ml                          1.1                          0.6, 2.0                              1.3                            0.7, 1.9                         0.069
RANTES                                   ng/ml                        45.3                        20.9, 119.4                        29.1                          17.1, 50.5                       0.086
Resistin                                     ng/ml                        17.8                        13.6, 27.8                         13.2                          10.3, 17.1                       0.197
SAA                                          mg/ml                       20.0                          7.8, 65.4                           9.0                            4.3, 20.8                       0.095
sCD40L                                     pg/ml                      143.0                        82.3, 391.6                     228.2                        119.1, 675.4                     0.476
SCF                                           pg/ml                        77.8                        53.5, 92.6                         59.7                          44.5, 75.6                       0.829
SDF-1α-β                                  ng/ml                          0.7                          0.5, 1.0                              0.8                            0.6, 1.0                         0.468
sEGFR                                       pg/ml                      522.3                      399.2, 742.2                     510.3                        379.6, 684.3                     0.760
sE-Selectin                                ng/ml                        56.2                        41.6, 69.5                         71.2                          55.3, 87.7                       0.020
sFasL                                         pg/ml                        65.4                        53.9, 72.5                         60.5                          51.2, 82.6                       0.143
sHer2                                         ng/ml                          5.1                          4.3, 5.9                              5.0                            4.4, 6.2                         0.094
sICAM-1                                  mg/ml                         0.8                          0.5, 1.1                              0.4                            0.3, 0.6                         0.183
sIL-2Rα                                     ng/ml                          1.1                          0.8, 1.5                              0.8                            0.6, 1.1                         0.004
sTNFRII                                    ng/ml                          8.7                          6.6, 12.9                           6.3                            5.5, 8.0                       <0.001
sVCAM-1                                 mg/ml                         1.1                          0.9, 1.2                              1.0                            0.9, 1.2                         0.478
TGF-α                                       pg/ml                        18.0                        12.0, 24.0                         33.2                          21.8, 61.7                       0.069
TGF-β1                                     ng/ml                          2.0                          1.3, 2.9                              2.0                            1.3, 2.5                         0.158
TSP-1                                        mg/ml                         5.7                          2.9, 8.2                              3.5                            1.7, 6.7                         0.401
TSP-2                                        ng/ml                          3.0                          2.2, 4.2                              2.7                            1.9, 3.6                         0.019
TNF-α                                       pg/ml                        22.7                        17.1, 30                            17.5                          13.9, 22                        <0.001
TNF-β                                       ng/ml                          0.3                          0.1, 0.6                              1.1                            0.7, 1.16                       0.767
TNFRI                                       ng/ml                          1.4                          1.0, 2.2                              1.0                            0.8, 1.2                         0.575
TPO                                           ng/ml                          0.7                          0.5, 1.2                              2.3                            1.3, 12.0                       0.174
TRAIL                                       pg/ml                      128.3                        82.5, 159.6                     110.0                          84.1, 137.7                     0.016
VEGF-A                                    pg/ml                      157.7                        98.2, 373.6                     175.2                          82.3, 283.7                     0.718
VEGF-C                                    ng/ml                          0.7                          0.5, 1.1                              0.8                            0.5, 1.1                         0.502
p-Values are from t-test and are unadjusted for multiple comparisons. 
Tools for implementing k-nearest neighbor classifiers as
discussed herein are available for the statistical software computing
language and environment, R. For example, the R package “e1071,”
version 1.5-25, includes tools for creating, processing and using k-
nearest neighbor classifiers.
Random forests. Classification trees are typically noisy. Random
forests attempt to reduce this noise by taking the average of many
trees. The result is a classifier whose error has reduced variance
compared to a classification tree.
To grow a forest: 
i) Use the algorithm 
For b=1 to B, where B is the number of trees to be grown in the
forest. 
ii) Draw a bootstrap sample.
iii) Grow a classification tree, Tb on the bootstrap sample.
iv) Output the set {Tb}1 B. This set is the random forest.
To classify a new observation using the random forest, classify
the new observation using each classification tree in the random
forest. The class to which the new observation is classified most
often amongst the classification trees is the class to which the
random forest classifies the new observation. Random forests reduce
many of the problems found in classification trees but at the price
of interpretability. 
Tools for implementing random forests as discussed herein are
available for the statistical software computing language and
environment, R. For example, the R package “randomForest,”
version 4.6-2, includes tools for creating, processing, and using
random forests.
Results
Biomarker characteristics. The median plasma concentrations
for all biomarkers were used to represent the central tendency
of the plasma concentrations to provide resistance to bias due
to skewed distributions and outliers as shown on Table IV and
Figure 1. The p-Values using the T-test, unadjusted for
multiple comparisons, are statistically significant at a 0.05
level for 25 of 82 biomarkers (Table IV). From a univariate
perspective, this indicates there are many biomarkers that
discriminated NSCLC from other pathologies to a degree.
The biomarkers were ordered based on importance in the
Random Forest model used to distinguish between NSCLC
and non-NSCLC samples (Table V). A biomarker’s
importance was defined as the decrease in Gini impurity (12)
between a model, including the biomarker, and one without
it. Thirty-three plasma proteins were selected based on
statistical and biological significance. We conclude that
gender is marginally significant, as otherwise shown in
previous studies done by Izbicka et al. (13), and race is not
an important factor. 
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Table V. Biomarker importance list. 
Biomarker                                Importance                             Biomarker                          Importance                       Biomarker                       Importance
MCP-1                                         15.138                           CCL20/MIP-3α                           7.680                              LIF                                     4.726
MMP-7                                        14.794                           HGF                                             7.410                              IL-1β                                 4.642
sCD40L                                       12.935                           PAI-1 total                                   7.171                              GM-CSF                            4.375
sE-Selectin                                  12.787                           CXCL11/ITAC                            7.057                              IL-12P70                           4.294
TNFRI                                         12.292                           MIP-1β                                        6.838                              IL-6                                    4.233
CA125                                         12.235                           Thrombospondin-1                      6.658                              IL-10                                  3.840
sICAM-1                                     12.194                           SCF                                              6.574                              IFNy                                  3.754
CEA                                             11.837                           NSE                                             6.457                              IL-12P40                           3.542
OPG                                             11.115                           SDF-1α/B                                    6.398                              IFNα2                                3.540
Leptin                                          11.048                           PLGF                                           6.174                              TGF-α                               3.448
SAA                                            10.923                           NGF                                             6.143                              IL-3                                    2.847
MMP-9                                         9.998                            sEGFR                                         6.021                              IL-16                                  2.517
IL-8                                              9.453                            IFNβ                                            5.919                              TPO                                   2.431
CXCL9-MIG                               9.296                            TNFα                                           5.914                              IL-5                                    2.318
MIF                                              9.273                            VEGF-C                                      5.858                              IL-20                                  2.080
GRO-pan                                      9.187                            sIL-2Ra                                        5.767                              MIP-1α                              2.017
sTNFRII                                       9.110                            IL-17A                                         5.756                              Gender                               1.484
IP-10                                             9.016                            IL-1Rα                                         5.740                              IL-9                                    1.335
MPO                                             9.015                            RANKL                                       5.706                              IL-2                                    1.227
THBS2                                         8.858                            sFasL                                           5.694                              IL-15                                  1.028
RANTES                                      8.754                            CYFRA21-1                                5.672                              MCP-3                               1.003
sHer2                                            8.530                            IL-23                                            5.587                              IL-7                                    0.889
sVCAM-1                                    8.292                            Granzyme-B                                5.579                              IL-4                                    0.581
Resistin                                        8.241                            IL-31                                            5.400                              IL-13                                  0.385
TRAIL                                          8.049                            IL-22                                            5.180                              TNFβ                                 0.302
PDGF-AB/BB                              7.947                            IL-17F                                          5.042                              Race                                   0.000
IL-1a, IL-21, IL-27, M-CSF, TGFb1 and VEGF-A were removed due to missing data. 
Multivariate analysis. To calculate the performance of the
model, we used 10-fold cross validation. The data was
divided into 10 partitions, using nine partitions to train and
evaluate the model on the remaining partition. The process
is repeated until all partitions are used to evaluate the model.
The average of all results from each step represents an
unbiased estimate of the model’s performance.
The results of the algorithm comparison indicated that the
Random Forest was the best algorithm, in conjunction with
the selected 33 biomarkers, to use for developing the
LCDT1. This model has an accuracy of 89.9%, sensitivity of
98.2%, and specificity of 86.5% for NSCLC (Table VI) in
the Training Set. 
AUC/ROC curves. The ROC Curve (Figure 2) for the 33
biomarkers have an AUC of 0.963. When other non-NSCLC
cancers were removed from analysis, the AUC improved to
0.974. This indicates potential for clinical use. 
Validation performance. An independent sample set of 925
(N=1,850) subjects was processed using the selected 33
biomarkers and developed classifier. The validation results
yielded 82% accuracy, 80.3% sensitivity, and 82.3%
specificity (Table VII). The cohorts consisted of 74 asthma
sufferers, 178 healthy non-smokers, 191 NSCLC, 168 high-
risk smokers, and 314 other cancer patients. The majority of
NSCLC samples were Stage I (Table III).
The performance of the algorithm improved when the
asthma and non-NSCLC cancers were removed from the data
set. A total of 537 samples (178 non-smokers, 191 NSCLC,
and 168 smokers) were included in this data set. The results
yielded an increase in accuracy to 90% and specificity to
95.4% with the sensitivity consistent at 80.3% (Table VII).
Significant markers. Biomarkers that were upregulated by
more than 50% using median concentration in lung cancer
patients compared to healthy non-smokers included IL-7
(530%), IL-10 (272%), SAA (268%), MMP-9 (251%), IL-8
(247%), Gro (226%), MIG (226%), Rantes (191%), TNFRI
(185%), and Resistin (150%). sCD40L and IL-5 showed a
56-57% down-regulation in NSCLC patients compared to
healthy non-smokers (Figure 1). 
The markers selected in our panel were a mixture of
markers that may be significant for NSCLC, Non-Smokers
(healthy), Smokers (high-risk, no cancer), and Asthma
sufferers. 
Assay precision. Inter-assay precision was determined using
a low and high-quality control processed in duplicates over
24 plates, performed over 4 days by 4 different operators
using 4 Luminex platforms. Biomarker inter-assay precision
was between 2.8-5.5% and 3.8-7.9% for all analytes using
MFI and concentration CV, respectively. Total plate %CV for
each plate ran for all panels were between 3.4-6.5% and 5-
11.4% for all analytes (using blanks, standards, QC and
samples) using MFI and concentration CV, respectively. No
cross-reactivity between analytes in each panel was observed.
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Table VI. 10-Fold cross-validation for 6 multivariate classification algorithms and 33 biomarkers.
                                Accuracy (CI)                     Sensitivity (CI)                    Specificity (CI)                         PPV (CI)                              NPV (CI)
RF                       0.899 (0.851-0.935)            0.982 (0.921-0.998)             0.865 (0.802-0.914)             0.747 (0.640-0.835)             0.992 (0.963-0.999)
AdaBoost           0.884 (0.834-0.923)            0.947 (0.866-0.985)             0.858 (0.794-0.901)             0.730 (0.621-0.821)             0.956 (0.937-0.993)
Lasso                  0.869 (0.816-0.910)            0.912 (0.818-0.968)             0.851 (0.785-0.902)             0.712 (0.602-0.806)             0.960 (0.915-0.985)
RR                      0.869 (0.816-0.910)            0.895 (0.796-0.955)             0.858 (0.794-0.901)             0.718 (0.607-0.813)             0.956 (0.937-0.993)
GA                      0.798 (0.738-0.849)            0.790 (0.671-0.879)             0.801 (0.730-0.861)             0.616 (0.502-0.723)             0.904 (0.843-0.946)
SVM                   0.864 (0.811-0.906)             0.877 (0.774-0.943)             0.858 (0.794-0.901)             0.714 (0.601-0.810)             0.945 (0.896-0.975)
NPV: Negative predictive value; PPV: positive predictive value; CI: 95% confidence interval; SVM: support vector machine; RF: random forest;
RR: ridge regression; GA: genetic algorithms. All values for model performance are calculated using a 10-fold cross validation and are by subject
results.
Table VII. Validation performance using the 33 biomarkers and
developed classifier.
                             A, NS, all cancers,                   NS, NSCLC, S 
                                 S (925 subjects)                       (537 subjects)
                          Value            95% CI:            Value             95% CI: 
                                              LCL, HCL                               LCL, HCL
Accuracy           0.820         0.794, 0.843         0.900          0.873, 0.924
Sensitivity          0.803         0.742, 0.855         0.803          0.742, 0.855
Specificity         0.823         0.742, 0.850         0.954          0.928, 0.972
PPV                    0.539         0.481, 0.597         0.904          0.853, 0.942
NPV                   0.942         0.922, 0.958         0.899          0.865, 0.927
LCL: Lower confidence limit; HCL: higher confidence limit; A:
Asthma; NS: non-smoker; S: smoker; NSCLC: non-small cell lung
cancer. All cancers include breast, ovarian, prostate, pancreatic, colon-
rectal cancer, and non-small cell lung cancer. PPV: positive predictive
value; NPV: negative predictive value.
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Discussion
Multiplex assays have been evaluated as a potential
diagnostic tool for lung cancer in numerous studies (13-19).
Several biomarkers that can statistically discriminate lung
cancer from healthy populations have been identified, and
our results correlate with these findings. Examples for such
biomarkers include (but are not limited to): i) CEA, ii)
CYFRA21-1, iii) NSE, iv) VEGF-C, v) MMP7, and vi)
MMP9. Independent lung tumor studies by Okamura et al.,
and Wieskopf et al., have shown a sensitivity range of 43%
and 59% with specificity of 89% and 94%, respectively, for
CYFRA21-1 in detecting LC (14, 15). CEA has been shown
to have a sensitivity of 69% and a specificity of 68% for LC
(14). For NSE, an SCLC detection sensitivity as high as 74%
has been reported (16). Tamura et al., (17) in 2004 showed
elevated serum levels for VEGF-C, MMP-9, and VEGF in
lung cancer patients with lymph node metastasis. These
markers had individual sensitivities of 85%, 63%, 80%, and
specificities of 68%, 75%, and 59%, respectively. The
performance of a combination of these 3 markers was at 83%
sensitivity and 76% specificity (17, 18). Other studies have
shown that Matrix Metallo-Proteinases expression is
associated with lung cancer tissue growth (19) and MMP-9
as a prognostic indicator of relapse in patients with lung
adenocarcinoma (20). Our results are consistent with
previous literature reports which indicate an increased
expression in MMP-7 (127%) and MMP-9 (251%) in lung
cancer patients (Figure 1).
Naturally, attempts have been made to improve the
diagnostic value of potential biomarkers using different
combinations (of markers and algorithms), aiming to develop
a product that would complement current gold standard
diagnostic methods for lung cancer. Such an example is
Paula’s Test (21), which uses 4 biomarkers (CEA,
CYFRA21-1, CA125, and NY-ESO-1) in blood serum and
has a sensitivity of 77% and a specificity of 80% using a
validation set (N=150) that includes NSCLC and healthy
cohorts. Another study performed by Somalogic (22, 23)
used 8 tissue homogenates and 1,326 serum NSCLC
samples, which resulted in the development of a 12-protein
panel (cadherin-1, CD30 ligand, endostatin, HSP90α,
LRIG3, MIP-4, pleiotrophin, PRKCI, RGM-C, SCF-sR, sL-
selectin, and YES). Somalogic’s panel could distinguish
NSCLC (Stage I-III) from controls, concluding with a
sensitivity of 89% and a specificity of 83% in their blind
study. In our study, the LCDT1 used 33 biomarkers in blood
plasma achieving a sensitivity of 80.3% and a specificity of
82.3% using a validation set of 925 subjects consisting of
NSCLC, asthma sufferers, smokers, non-smokers, and other
cancer patients. Notably, specificity increased to 95.4% when
samples were restricted to NSCLC from healthy controls
(e.g. smoker, non-smoker) (Table VII). 
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The enhanced performance in the algorithm when non-
NSCLC cancers and asthma were removed may indicate that
i) the number of non-NSCLC cancer and asthma samples
were insufficient to create a model that distinguished the
differences between these samples, and/or ii) other cancers
and asthma may have a masking effect on the NSCLC
population affecting the results. This phenomenon requires
further investigation.
The combinations of biomarkers, algorithms, sample types,
and platforms displayed varying results. We found that the
number of proteins (too few), as well as selectivity of these
protein markers (too general), in a panel can cause the test to
become generic (or applicable) to many cancers rather than to
a specific one. This effect can be attributed to the pleiotropic
nature of many of these proteins and overlapping signal
response pathways of the immune system. A combination of
markers that are individually significant, or those that may
even exhibit a pattern between cohorts, for asthma sufferers
(or COPD), NSCLC, smokers, and non-smokers, may
augment the discrimination effects of the algorithm. 
From an overall set of 351 NSCLC samples, 90.3% were
Stage I, 2.3% were Stage II, and 7.4% were Stage III/IV
(Table III). Our validation results illustrate the algorithm’s
ability to detect NSCLC, i.e., especially Stage I, with an 82%
(95%CI: 79-84) accuracy, 80.3% (95%CI: 74-85) sensitivity,
82.3% (95%CI: 74-84) specificity, 53.9% (95%CI: 48-60)
PPV, and 94.2% (95%CI: 92-96) NPV. The International
Early Lung Cancer Action Program Investigators (24)
showed that LC patients who were diagnosed at Stage I and
underwent a surgical resection (e.g. lobectomy, wedge
resection, segmentectomy, and bilobectomy) one-month post
diagnosis had a 92% (95%CI: 88-95) 10-year survival rate. 
Currently, Medicare covers the use of LDCT for lung
cancer screening using the eligibility criteria for the NLST to
define high-risk individuals. Ma et al., estimated that at least
8.6 million Americans qualified as high risk for lung cancer
and were recommended to receive annual screening with low-
dose CT scans in 2010 (25). A study by Brenner et al., have
estimated that in individuals between the ages of 50-70 who
undergo an annual CT screen for lung cancer, a total of 1,080
(230 males and 850 females) of 100,000 screened will
develop a radiation-related cancer (26, 27). About 2% (95%
uncertainty limits, 1%-3%) of the 1.4 million cancers
diagnosed in the United States in 2010 could be related to CT
scans (27, 28). Hence, a simple blood-based test could
significantly reduce radiation-related cancers in the future.
Multiplex immunoassays have been evaluated as a potential
diagnostic tool for lung cancer in numerous studies. However,
the variability of commercially available protein assays due to
the complex nature of proteins (i.e., structure, stability,
interactions) has made the translation process of immunoassays
into diagnostic tools challenging. A final product would
necessitate the development of a consistent reagent kit using an
optimal combination of biomarkers coupled with an algorithm
that has been thoroughly validated and revalidated for
functionality and clinical utility. At present, we have simplified
our model by decreasing the number of variables to a subset of
21 biomarkers (from the 33) with promising results (Figure 1). 
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Figure 2. AUC/ROC graphs. 
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